| City: |
|
Bethesda |
|
State:
|
|
MD |
| Zip Code: |
|
20892 |
| Conditions: |
|
Idiopathic CD4 Positive T Lymphocytopenia - Cryptococcal Meningitis - Warts |
| Purpose: |
|
Background:
- Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased
level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic
infections or autoimmune disorders and diseases.
Objectives:
- To characterize the natural history with regard to CD4+ T cell count and onset of
infection, malignancy, and autoimmunity.
- To describe the immunological status of patients affected by ICL while providing the
best possible standard therapy to eradicate opportunistic infections.
- To establish the timeline of CD4 lymphocytopenia, with particular focus on defining
subgroups of patients according to the decline, stabilization, or rise of CD4+ T cell
counts over time.
- To characterize the opportunistic infections that occur in ICL patients at
microbiologic and molecular levels.
- To characterize the immunophenotype and possible genetic immunodeficiency causes of
ICL.
- To determine whether measurable immunologic parameters correlate with the development
of opportunistic infections or other comorbidities such as lymphoma in patients with
ICL.
- To determine whether there is any association between ICL and autoimmunity.
- To determine CD4+ T cell turnover, survival, functionality, and cytokine responsiveness
in ICL patients.
Eligibility:
- Patients 2 years of age and older with an absolute CD4 count less than 300 in children
6 years or older and adults or less than 20% of T cells in children younger than 6 on
two occasions at least 6 weeks apart.
- Patients with negative results of HIV testing by ELISA, Western Blot, and viral load.
- Patients must not have underlying immunodeficiency conditions, be receiving cytotoxic
chemotherapy (anti-cancer drugs that kill cells), or have cancer.
Design:
- At the initial visit to the National Institutes of Health, the following evaluations
will be conducted:
- Personal and family medical histories.
- Physical examination, including rheumatology evaluation and other consultations as
medically indicated (e.g., dermatology, pulmonology, ophthalmology, imaging studies).
- Blood samples for analysis of red and white blood cell counts, liver function, immune
hormones, and antibody and autoantibody levels, white blood cell growth and function,
and DNA.
- Urinalysis and urine pregnancy testing for female patients of childbearing age.
- Evaluation and treatment of active infections as medically indicated, including
biopsies, buccal swabs, pulmonary function tests, and imaging studies.
- Follow-up visits will take place approximately every 12 months or more frequently if
indicated, and will continue for a minimum of 4 years and a maximum of 10 years.
- Evaluations at follow-up will include blood samples (i.e., CBC with differential,
biochemical profile, HIV testing, etc.) and urinalysis and rheumatology consults.
|
| Study summary: |
|
Idiopathic CD4+ lymphocytopenia (ICL) is a disorder characterized by decreased numbers of
circulating CD4+ T lymphocytes in the absence of known causes of CD4+ lymphocytopenia. ICL
is defined as an absolute CD4+ T cell count of less than 300 cells/mL in a patient with no
human immunodeficiency virus infection or known immunodeficiency syndrome. The causes and
frequency of the disorder remain unknown. The condition is typically diagnosed when patients
present with a serious infection. In this natural history protocol, we will evaluate
patients with CD4+ T cell counts below 300 cells/microL. We propose to follow 100 patients
for a minimum of 4 and maximum of 10 years, with a particular focus on the association
between ICL and autoimmune disease. We will collect blood for immunologic, rheumatologic,
and genetic testing in an effort to identify and understand the underlying defects that
cause ICL and follow its course in a cohort of patients who will receive best standard
therapy for opportunistic infections. |
| Criteria: |
|
- INCLUSION CRITERIA:
To be eligible for this study, patients must satisfy all of the following inclusion
criteria:
- Age greater than or equal to 2 years
- Absolute CD4 count < 300 cells/microL or < 20% of total T cells in children greater
than or equal to 6 years old and adults on at least two occasions at least 6 weeks
apart; or CD4+ percentage < 20% of normal on 2 occasions at least 6 weeks apart in
children < 6 years old
- Ongoing care by a referring primary care physician
- Willingness to allow storage of blood and tissue samples for future analysis
EXCLUSION CRITERIA:
Patients will be ineligible for this study if they satisfy any of the following criteria:
- Known infection with HIV-1, HIV-2, or human T-cell lymphotropic viruses (HTLV-1 or
HTLV-2) as demonstrated by ELISA and Western blot and/or viral load testing
- Known underlying immunodeficiency syndrome
- Evidence of active malignancy
- Receipt of medications, herbal substances, or biologic agents known to diminish the
CD4+ count within 30 days of when the CD4+ lymphocytopenia was detected
- Any condition that in the judgment of the investigators would place the subject at
undue risk or compromise the results of the study. |
|
|
|
| Study is available at: |
|
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, MD 20892
United States
Primary Contact:
Patient Recruitment and Public Liaison Office
Email: prpl@mail.cc.nih.gov
Phone: (800) 411-1222 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|